CASI Pharmaceuticals, Inc. (CASI) — Financial statements
Income statement, balance sheet, and cash flow for CASI Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 29↓15.8% | 34↓21.4% | 43↑42.9% | 30↑99.2% | 15 | |
| Cost of Revenue | 17↑25.8% | 14↓12.6% | 16↑26.0% | 13↑32.1% | 10 | |
| Gross Profit | 11↓44.4% | 20↓26.5% | 27↑54.9% | 18↑212.6% | 6 | |
| Operating Expenses | ||||||
| R&D Expenses | 9↓9.6% | 10↓38.4% | 16↑10.9% | 14↑25.7% | 11 | |
| General & Administrative Expenses | 24↓7.1% | 25↑8.3% | 23↓1.1% | 24↑20.5% | 20 | |
| Selling & Marketing Expenses | 18↑8.6% | 16↑14.8% | 14↓2.6% | 15↑88.2% | 8 | |
| SG&A Expenses | 41↓0.9% | 42↑10.8% | 38↓1.6% | 38↑39.8% | 27 | |
| Other Expenses | 0.41↑106.2% | -7 | 0.00↓100.0% | 6↓67.6% | 19 | |
| Operating Expenses | 51↑12.5% | 45↓16.1% | 54↓9.1% | 59↑1.2% | 58 | |
| Total Costs & Expenses | 68↑15.6% | 59↓15.3% | 70↓2.9% | 72↑5.5% | 68 | |
| Operating Results | ||||||
| Operating Income | -40↓58.0% | -25↑5.3% | -26↑36.2% | -42↑21.3% | -53 | |
| Depreciation & Amortization | 2↓37.7% | 4↑54.5% | 2↑33.4% | 2↓7.4% | 2 | |
| EBITDA | -35↓61.9% | -22↑10.5% | -24↑27.9% | -33↓6.5% | -31 | |
| EBIT | -37↓47.1% | -25↑4.6% | -26↑24.8% | -35↓5.7% | -33 | |
| Interest & Other Income | ||||||
| Net Interest Income | -0.33↓154.1% | 0.61↑383.5% | 0.13↓60.4% | 0.32↓62.9% | 0.87 | |
| Interest Income | 0.54↓12.2% | 0.61↑224.9% | 0.19↓41.1% | 0.32↓62.9% | 0.87 | |
| Interest Expense | 0.87 | 0.00↓100.0% | 0.06 | 0.00 | 0.00 | |
| Non-Operating Income | -2↓1311.5% | 0.20 | 0.00↑100.0% | -6↑67.6% | -19 | |
| Other Income / Expenses | 2↑228.1% | -1↑89.7% | -12↓307.7% | 6↑7.7% | 5 | |
| Income Before Tax | -38↓44.8% | -26↑31.3% | -38↓6.8% | -36↑24.6% | -48 | |
| Income Tax Expense | 1↑1567.9% | -0.08↓104.1% | 2 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -39↓49.8% | -26↑34.9% | -40↓12.3% | -36↑24.6% | -48 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -39↓45.7% | -27↑34.3% | -41↓11.9% | -37↑24.1% | -48 | |
| Bottom-Line Net Income | -39↓45.6% | -27↑34.3% | -41↓11.9% | -37↑24.1% | -48 | |
| EPS (Basic) | -2.56↓26.7% | -2.02↑32.9% | -3.01↓11.9% | -2.69↑38.4% | -4.37 | |
| EPS (Diluted) | -2.56↓26.7% | -2.02↑32.9% | -3.01↓11.9% | -2.69↑38.4% | -4.37 | |
| Weighted Average Shares | 15↑14.8% | 13↓2.1% | 14↑0.3% | 14↑23.2% | 11 | |
| Weighted Average Diluted Shares | 15↑14.8% | 13↓2.1% | 14↑0.3% | 14↑23.2% | 11 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.